



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 26 Jul 2022 (#29)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-HD-22-033](#) Notice of Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Participation in [PAR-22-151](#) Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional). Due dates 22 August 2022, 2023 & 2024. The purpose of this FOA is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country.

[NOT-HD-22-034](#) Notice of Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Participation in [PAR-22-152](#) Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed). Due dates 22 August 2022, 2023 & 2024. This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program.

[NOT-HL-22-026](#) Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in [PAR-22-105](#) Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). Due dates 5 October 2022 through to 7 May 2025 Applications for studies (clinical trial optional) relevant only to a particular disease or organ system should be directed to the appropriate Division or Center at NHLBI. The Divisions of Cardiovascular Science, Lung Diseases, Blood Diseases and Resources, and the Center for Translational Research and Implementation Science all accept applications to this FOA. NHLBI encourages potential applicants to contact program staff for assistance early in

the application process, particularly if you need assistance in identifying where to direct your application. Applications proposing clinical trials may require additional information at the time of award and additional NHLBI oversight.

[NOT-HL-22-041](#) Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in [PAR-22-104](#) Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional). Due dates 13 July 2023 & 15 July 2024. The National Heart, Lung, and Blood Institute (NHLBI) is interested in training programs that sustainably strengthen heart, lung, blood, and sleep (HLBS) research capacity of low- and middle-income country institutions; train in-country experts to develop and conduct research on HLBS diseases and disorders across the lifespan; and maximize NHLBI's current global health investments, with the long-range goal of developing and implementing evidence-based, contextualized HLBS interventions to reduce the burden of chronic diseases. Examples of HLBS diseases and disorders include, but are not limited to, hypertension, obesity, rheumatic heart disease, chronic obstructive lung diseases, asthma, and sickle cell disease. Training programs across the spectrum of research disciplines is encouraged, from basic biomedical, behavioral, and social science to clinical and applied sciences, including translational and implementation science that emphasizes the resources, context, and needs of multiple stakeholders in local settings. Training programs should include research skills, research design and methodology, ethics, data management and analysis, grant writing, manuscript writing, scientific presentations and research administration.

[NOT-AI-22-061](#) Notice of Intent to Publish a Funding Opportunity Announcement for Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) U01 Clinical Trial Not Allowed. National Institute of Allergy and Infectious Diseases ([NIAID](#)) intends to publish a FOA to solicit applications for an Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC). The AA-SCCC will provide a broad range of support critical for design, development, execution, and analysis of clinical research in allergic diseases and asthma. The types of research for which support will be provided include clinical trials, integrated studies of underlying mechanisms, clinical studies (e.g., longitudinal observational studies, genetic studies, etc.), and studies to identify and validate surrogates/biomarkers. This Notice is being provided to allow potential applicants more time to consider the requirements of the AA-SCCC and develop responsive applications. The FOA is expected to be published in August 2022. First Estimated Application Due Date: November 30, 2022. NIAID intends to fund one award. Estimated Award Ceiling \$9,000,000 Non-domestic (non-U.S.) Entity (Foreign Organization) is eligible to apply.

[NOT-AI-22-062](#) Notice of Intent to Publish a Funding Opportunity Announcement for Transplantation Statistical and Clinical Coordinating Center (T-SCCC) U01 Clinical Trial Not Allowed. National Institute of Allergy and Infectious Diseases ([NIAID](#)) intends to publish a FOA to solicit applications for the Transplantation Statistical and Clinical Coordinating Center (T-SCCC) to provide a broad range of support critical for the design, development, execution, and analysis of clinical research carried out by multiple NIAID-supported programs in transplantation. The awardee will provide a broad range of support critical for the design, development, implementation, and analysis of clinical research carried out by multiple NIAID-supported programs in transplantation. The scope of support to be provided includes statistical design and analysis, protocol development, final analysis of study findings, establishment and maintenance of a biospecimen tracking database, and support for the mechanistic studies by providing biospecimen labeling, shipping, and kits and/or bulk supplies for specimen collection. The FOA is expected to be published in August 2022. First Estimated Application Due Date: November 30, 2022. NIAID intends to fund one award. Estimated Award Ceiling \$9,000,000 Non-domestic (non-U.S.) Entity (Foreign Organization) is eligible to apply.

[NOT-AI-22-063](#) Notice of Intent to Publish a Funding Opportunity Announcement for National Institute of Allergy and Infectious Diseases (NIAID) Clinical Data and Safety Management Center (CDSMC) (U01 Clinical Trial Not Allowed). National Institute of Allergy and Infectious Diseases ([NIAID](#)) intends to promote a new initiative by publishing a FOA to solicit applications establishing a Clinical Data and Safety Management Center (CDSMC). The CDSMC will provide a broad range of clinical support services, including data management and processing, safety and pharmacovigilance management and processing, and sample tracking systems or NIAID-funded clinical trials, integrated studies of underlying mechanisms, clinical studies (e.g., longitudinal studies, genetic studies), and studies to identify and validate surrogates/biomarkers of immune-mediated diseases in the areas of asthma and allergic diseases, autoimmune diseases, and transplantation. The FOA is expected to be published in August 2022. First

Estimated Application Due Date: November 30, 2022. NIAID intends to fund one award. Estimated Award Ceiling \$9,000,000 Non-domestic (non-U.S.) Entity (Foreign Organization) is eligible to apply.

Notice of Special Interest (NOSI)

[NOT-DE-22-003](#) Notice of Special Interest (NOSI): Single-Cell Level Spatiotemporal Mapping of Dental and Craniofacial Embryogenesis. The National Institute of Dental and Craniofacial Research ([NIDCR](#)) is issuing this Notice of Special Interest (NOSI) to encourage research that applies cutting edge imaging and high-throughput 'omics approaches at the single-cell level to understand the complex spatiotemporal context of the developing dental and craniofacial tissues in the embryo. This notice applies to due dates on or after 28 September 2022 and subsequent receipt dates through 8 September 2025.

[NOT-HL-22-025](#) Notice of Special Interest (NOSI): Respiratory Complications of the Muscular Dystrophies (R01). The purpose of this NOSI is to encourage research grant applications focused on respiratory complications of the muscular dystrophies. This includes further elucidation of respiratory phenotypes in humans; research to optimize pulmonary function testing and existing respiratory therapies in humans; and mechanistic and translational research, including in vitro and in animal models, that examines respiratory muscle response to gene therapies and other therapeutic strategies in the muscular dystrophies. This NOSI encourages scientists in the space of muscular dystrophies to investigate respiratory function, and scientists in sleep-disordered breathing, ventilatory control and respiratory pathobiology and physiology to bring their expertise to research in the respiratory implications of these neuromuscular diseases. There is a possibility of cross-collaboration between disciplines that will bring synergy to research in diseases that are primarily neuromusculoskeletal with a profound and debilitating impact on the patient's quality of life, largely due to pulmonary limitation. This is an opportunity to understand ways to effectively help patients remain in optimal pulmonary health for responding to currently available therapies, and potentially to future innovative therapies that are in the pipeline. This notice applies to due dates on or after 25 September 2022 and subsequent receipt dates through 7 January 2025.

Funding Opportunity Announcements (FOA)

1. Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN) Clinical Research Centers (UG1 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-23-013](#)

Type: UG1

Application Due Date: 6 December 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN). The Network will expand and/or improve successes achieved by PATC³H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by [UNAIDS estimates](#) as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more. The structure of PATC³H-IN shall consist of two highly integrated components - (1) Clinical Research Centers (CRC) (each center will propose a study to be executed in at least 5 research performance sites); and (2) a single Coordination, Translation and Advanced Methods and Analytics Center (CTAMAC). This FOA solicits applications for Clinical Research Centers (CRC). There is a parallel companion FOA that seeks applications for a single Coordination, Translation and Advanced Methods and Analytics Center (CTAMAC) ([RFA-HD-23-014](#)).

Budget: NICHD and partner [components](#) intend to commit an estimated total of \$8,000,000 to fund approximately 4-5 awards for fiscal year 2023, subject to funding availability. Future amounts will depend on annual appropriations. Application budgets are limited to \$940,000 per year in direct costs. The scope of the proposed project should determine the project period and may be up to 5 years.

2. PATC3H Implementation Science Network (PATC3H-IN) Coordination, Translation and Advanced Methods and Analytics Center (UM2 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-23-014](#)

Type: UM2

Application Due Date: 6 December 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications to participate in a research program cooperative agreement to support the Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC³H-IN). The Network will expand and/or improve successes achieved by PATC³H to new geographic settings with limited implementation science (IS) research capacity and/or risk populations who are poorly represented in international adolescent HIV research (e.g. sexual and gender minorities; commercial sex workers; drug users) and stimulate much needed IS research in a neglected area of public health significance: prevention of new HIV infections among adolescents at risk and the identification of, and linkage and retention to care of and long-term viral suppression among youth living with HIV in low-to-middle income countries (LMICs). These settings must have an HIV epidemic density defined by [UNAIDS estimates](#) as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV incidence among youth ages 10 to 24 years of 0.01% or more. The structure of PATC³H-IN shall consist of two highly integrated components - (1) Clinical Research Centers (CRC) (each center will propose a study to be executed in at least 5 research performance sites); and (2) a single Coordination, Translation and Advanced Methods and Analytics Center (CTAMAC). This FOA solicits applications for a single Coordination, Translation and Advanced Methods and Analytics Center (CTAMAC). There is a parallel companion FOA that seeks applications for Clinical Research Centers (CRC) ([RFA-HD-23-013](#)).

Budget: NICHD and partner [components](#) intend to commit an estimated total of \$4,000,000 to fund one award for fiscal year 2023, subject to funding availability. Future amounts will depend on annual appropriations. Application budgets are limited to \$2,500,000 per year in direct costs. The scope of the proposed project should determine the project period and may be up to 5 years.

3. BRAIN Initiative: Brain Behavior Quantification and Synchronization (R61/R33 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-22-240](#)

Type: R61/R33

Application Due Date: 17 February 2023; February 15, 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports the development and validation of next-generation tools, methods, and analytic approaches to precisely quantify behaviors and combine them with simultaneous recordings of brain activity in humans. Tools used for measuring and analyzing behavior should be multi-modal, with the appropriate accuracy, specificity, temporal resolution, and flexibility necessary for integration with existing tools used to measure and modulate the brain circuits that give rise to those behaviors. This R61/R33 FOA is intended to support biphasic applications for novel tools development (i.e., hardware/software) in the R61 phase, followed by the integration/synchronization of these novel tools with established methods for recording human brain activity in the R33 phase. Applications must propose one or more milestones, which clearly define the criteria for the success of the R61 project objectives. Transition to the R33 phase will depend on demonstration of milestone completion. Applications should be submitted by multi-disciplinary teams with expertise spanning behavior and behavioral measurement, neurobiology, social systems, computer/data systems, engineering, biostatistics, neuroethics, and artificial intelligence. Applicants pursuing brain-behavior quantification and synchronization tool development in non-human animals, or pursuing comparative animal studies including humans, are not responsive to this FOA and should consider related Brain-Behavior Quantification and Synchronization (BBQS) opportunities listed on the BRAIN Initiative website, or reach out to the contacts (see Section VII: Agency Contacts) for guidance on relevant opportunities.

Budget: NIMH and partner components intend to commit an estimated total of \$10 million to fund 8-10 awards in FY2024 and an estimated total of \$10 million to fund 8-10 awards in FY2025. Application budgets are not limited but need to reflect the actual needs of the proposed project. The proposed project period for the R61 must not exceed 4 years. The proposed project period for the R33 must not exceed 2 years. The total duration of the R61 and R33 may not exceed 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](#)
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krottoa Building, Ryneveld Street
Enquiries: [Lizél](#)
e: lizelk@sun.ac.za | t: +27 21 808 2105